Loading...
XSTO
QUIA
Market cap3mUSD
Apr 11, Last price  
0.02SEK
1D
77.06%
1Q
82.08%
Jan 2017
-99.99%
IPO
-100.00%
Name

QuiaPEG Pharmaceuticals Holding AB

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
163.21%
Rev. gr., 5y
5.31%
Revenues
0k
-100.00%
9,170,00010,228,0009,680,00012,701,0009,695,00013,057,0009,268,00014,400,000916,0003,932,0003,377,0004,466,0001,861,000216,0005,574,0004,374,0000
Net income
-29m
L+75.08%
753,00048,00074,000376,000-3,085,000-1,672,000-674,000578,0009,595,000-4,468,000-12,052,000-21,107,000-30,486,000-22,431,000-24,384,000-16,523,000-28,929,000
CFO
-10m
L-0.93%
956,0001,824,0002,646,0002,551,000-5,209,0002,206,0001,487,000487,0001,798,0000-10,392,000-15,112,000-28,308,000-20,110,000-18,178,000-10,266,000-10,171,000
Dividend
Mar 30, 20170.0239 SEK/sh

Profile

QuiaPEG Pharmaceuticals Holding AB (publ), a biotech company, develops biopharmaceutical products for the treatment of metabolic disorders. It develops biopharmaceuticals based on PEGylation technology platform, which is applicable on proteins, peptides, and small molecules or oligonucleotides. The company has strategic collaboration with Cobra Biologics AB for the refinement of biopharmaceutical products. The company was formerly known as Oligovation AB and changed its name to QuiaPEG Pharmaceuticals Holding AB (publ). QuiaPEG Pharmaceuticals Holding AB (publ) was founded in 2012 and is headquartered in Solna, Sweden.
URL
https://www.quiapeg.com/
IPO date
Jun 21, 2005
Employees
4
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
4,374
-21.53%
5,574
2,480.56%
Cost of revenue
(332)
6,184
8,026
Unusual Expense (Income)
NOPBT
332
(1,810)
(2,452)
NOPBT Margin
Operating Taxes
4,295
Tax Rate
NOPAT
332
(1,810)
(6,747)
Net income
(28,929)
75.08%
(16,523)
-32.24%
(24,384)
8.71%
Dividends
Dividend yield
Proceeds from repurchase of equity
23,432
13,675
22,477
BB yield
Debt
Debt current
20,611
315
Long-term debt
15,207
Deferred revenue
Other long-term liabilities
(15,207)
Net debt
(2)
20,510
12,956
Cash flow
Cash from operating activities
(10,171)
(10,266)
(18,178)
CAPEX
(460)
(5,574)
Cash from investing activities
(460)
(24,374)
(5,574)
Cash from financing activities
10,532
32,175
20,977
FCF
1,859
728
(4,747)
Balance
Cash
2
101
2,566
Long term investments
Excess cash
2
2,287
Stockholders' equity
23,783
2,621
(20,112)
Invested Capital
16,352
35,862
37,852
ROIC
1.27%
ROCE
2.03%
EV
Common stock shares outstanding
74,499
3,586
Price
Market cap
EV
EBITDA
332
2,049
916
EV/EBITDA
Interest
265
1,013
4,295
Interest/NOPBT
79.82%